The two forms

CJC-1295 DAC vs no DAC

Both names suggest a similar peptide. Only the DAC form carries the attachment that lets albumin prolong its time in the bloodstream.

Return to the pulse result Study amounts and their limits

Albumin attachment

The original albumin-binding design was examined in rats and laboratory stability tests. CJC-1295 combines four stabilising substitutions with an extra chemical handle. That handle forms a covalent bond—a lasting chemical attachment—to circulating albumin, a blood protein removed slowly from circulation.

DAC stands for Drug Affinity Complex. “CJC-1295 with DAC” and “CJC-1295 DAC” refer to this long-acting form. The attachment adds a way to prolong exposure beyond the chain changes themselves. I admire this use of albumin: the peptide makes use of a protein already travelling through blood.

That admiration is for the chemistry. The human question still concerns what the resulting, prolonged hormone stimulation does over time. The pulse measurements show why a continuing rhythm can accompany a raised basal GH level.

A pale paper peptide strand is joined to a larger folded green form by a small clasp — A paper-sculpture illustration of the albumin attachment. The shapes are symbolic rather than a molecular structure.

Modified GRF 1-29

The short-acting form retains the four changes in the GHRH-derived chain but lacks the albumin-binding addition. The Modified GRF (1-29) reference description distinguishes it from the long-acting DAC compound. “CJC-1295 no DAC” is a common name for that shorter-acting peptide.

The changes occur at positions 2, 8, 15 and 27 in the chain. Positions describe the sequence; they say nothing about an administered amount. Without the DAC attachment, the peptide disappears over minutes or hours. That gives the abbreviation a great deal of practical importance when interpreting any timing claim.

Half-life and IGF-1 duration

The healthy-adult CJC-1295 study estimated a half-life of 5.8-8.1 days for the DAC form. Half-life describes the time taken for the measured amount to fall by half. The same work reported IGF-1 remaining above baseline up to 28 days after multiple study doses.

I treat those as separate entries. The half-life describes disappearance of the peptide; the IGF-1 result describes a hormonal response under the tested conditions. Neither provides an established treatment schedule. The no-DAC description, meanwhile, concerns a short-acting form that cannot inherit the DAC study’s multi-day finding simply by sharing the CJC-1295 name.

Chemical registries also disagree on some exact formula listings for CJC-1295. That is another reason a name alone leaves too much unresolved about a material’s identity. The analytical identification of a seized preparation required laboratory testing. The study identified a substance; it did not establish treatment quality or safety.